IDEXX Laboratories ($IDXX) CEO & Director Files Form 144 for $17.68M Proposed Sale

Executive Summary

On November 4, 2026, Jonathan Jay Mazelsky, Officer and Director of IDEXX Laboratories, Inc. (NASDAQ: IDXX), filed a Form 144 notice disclosing the intent to sell 25,140 shares of common stock through Morgan Stanley Smith Barney LLC. The aggregate market value of the proposed transaction is $17,678,196.60, representing an estimated price of approximately $703.19 per share.

Transaction Details

• Security: Common Stock
• Units Proposed for Sale: 25,140
• Estimated Aggregate Market Value: $17,678,196.60
• Approximate Sale Date: November 4, 2026
• Acquisition Origin: Acquired on November 4, 2026, via cash exercise of stock options directly from the issuer.
• Past Sales: No securities sold in the past three months reported on this filing.

Market Impact & Context

With an outstanding share count of 78,786,265 shares, this proposed sale represents approximately 0.03% of IDEXX Laboratories' total outstanding common equity. Although the dilution and relative ownership percentage impact is minimal, the absolute monetary value ($17.68M) combined with the insider's status as a key officer and director warrants a High significance rating. Investors should note this represents option-exercise monetization.